search
Back to results

Virtual Reality for AnxIety Disorders - Randomized Controlled Trial (VR8)

Primary Purpose

Social Anxiety, Social Phobia

Status
Recruiting
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Cognitive behavioral therapy with exposure in virtual reality
Cognitive behavioral therapy with exposure in vivo
Sponsored by
Region of Southern Denmark
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Social Anxiety focused on measuring Social anxiety, Cognitive behavioral therapy, Virtual reality, Exposure, Psychophysiological Measurement, Heart Rate, Electrodermal Activity

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Sufficient knowledge of the Danish Language.
  • Fulfilling the diagnostic criteria for SAD according to ICD-10 classification of mental and behavioral disorders (F 40.1).

Exclusion Criteria:

  • Previously diagnosed with autism spectrum disorders.
  • Previously diagnosed with psychotic disorders.
  • Severe depression (>29 Major Depression Inventory)
  • Dependence syndrome
  • Suicidal ideation.
  • Dementia/Intellectual disability.
  • Epilepsy.
  • Taking part in other kinds of psychological intervention for SAD.
  • Medication (SSRI, benzodiazepine, MAOI) type and doses needs to be stable three months prior to inclusions and during the intervention.

Sites / Locations

  • Centre for TelepsychiatryRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Cognitive behavioral therapy with exposure in virtual reality

Cognitive behavioral therapy with exposure in vivo

Arm Description

This arm of the study will receive cognitive behavioral therapy with exposure in virtual reality. The intervention is individual and manualized and delivered by a psychologist. The intervention consists of 10 weekly session with a duration of 60 minutes. Exposure is conducted from session 4 to 9. Homework is assigned and it includes exposure in vivo. The amount of exposure is controlled for.

This arm of the study will receive cognitive behavioral therapy with exposure in vivo. The intervention is individual and manualized and delivered by a psychologist. The intervention consists of 10 weekly session with a duration of 60 minutes. Exposure is conducted from session 4 to 9. Homework is assigned and it includes exposure in vivo. The amount of exposure is controlled for.

Outcomes

Primary Outcome Measures

Social Anxiety Interaction Scale
The instrument is a measure of social anxiety symptoms and consists of 20 items assessing cognitive, affective, and behavioral responses to social interaction. The scale ranges from 0 to 80. Higher scores indicate worse outcome. Participants have to indicate to what degree they feel each statement is characteristic to them using a 5-point Likert scale (0 = not at all, 1 = slightly, 2 = moderately, 3 = very, 4 = extremely). The instrument has high internal consistency, Cronbach's alpha = 0.93, and high test-retest reliability, r = 0.92 (45).

Secondary Outcome Measures

Leibowitz Anxiety Scale - Self report version
Leibowitz Anxiety Scale - Self report version is a measure of anxiety and avoidance in a range of social situations.
Fear of Negative Evaluation - Brief version
Fear of Negative Evaluation - Brief version is a measure of distress experiences when getting negative evaluations by others.
Major Depression inventory
Major Depression inventory is a measure of symptoms severity in depression.
EQ-5D-5L
EQ-5D-5L is a measure of health status.
Alcohol Use Disorders Identification Test
Alcohol Use Disorders Identification Test is a screening for unhealthy alcohol use.
Drug use disorders identification test
Drug use disorders identification test is a screening instrument for drug-related problems.

Full Information

First Posted
March 9, 2022
Last Updated
April 25, 2022
Sponsor
Region of Southern Denmark
Collaborators
University of Southern Denmark, Odense University Hospital, Universite du Quebec en Outaouais, IMotions A/S
search

1. Study Identification

Unique Protocol Identification Number
NCT05302518
Brief Title
Virtual Reality for AnxIety Disorders - Randomized Controlled Trial
Acronym
VR8
Official Title
Virtual Reality for AnxIety Disorders - Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
April 2022
Overall Recruitment Status
Recruiting
Study Start Date
March 31, 2022 (Actual)
Primary Completion Date
January 31, 2024 (Anticipated)
Study Completion Date
January 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Region of Southern Denmark
Collaborators
University of Southern Denmark, Odense University Hospital, Universite du Quebec en Outaouais, IMotions A/S

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Social anxiety disorder (SAD) has a high prevalence and an early onset and has a lengthy recovery period often taking decades to occur. Current evidence supports the efficacy of cognitive behavioral therapy (CBT) with virtual reality (VR) exposure. However, the evidence is based on a small number of studies. This trial examines the efficacy of an intervention that combines CBT with individually tailored exposure in VR. During exposure, participants' anxiety level is estimated in real time based on heart rate and electrodermal activity. Estimated anxiety level can guide the therapist's adjustment of the VR content. The above treatment is compared with the gold standard treatment for SAD which is cognitive behavioral therapy with exposure conducted in real life. Treatment is individual, manual-based and consists of 10 weekly sessions with a duration of 60 minutes. The aim of the study is to investigate whether CBT combined with exposure in VR (adapted on the basis of estimated anxiety level) is more effective than CBT with exposure in real life. The trial is a randomized controlled trail (RCT). The study includes 90 participants diagnosed with SAD. Assessments are carried out pre-treatment, mid-treatment and at follow-up (6 and 12 months). The primary outcome of the study is self-reported symptoms of social anxiety using Social Interaction Anxiety Scale. The primary endpoint is post-treatment.
Detailed Description
INTRODUCTION Social anxiety disorder (SAD) is a common anxiety disorder characterized by excessive fear of being scrutinized or criticized by others leading to avoidance of social situations. According to the ICD-10 classification of mental and behavioral disorders, engaging in feared situations is accompanied by autonomic symptoms of anxiety such as sweating, trembling or increased heartrate (HR). The lifetime prevalence of SAD ranges between 8.4% and 12.1% and the 12 month prevalence ranges between 4.2% and 7.1%. SAD is related to reduced health-related quality of life and is also associated with substantial psychiatric comorbidity including other anxiety disorders, mood disorders and substance use disorders. Epidemiological studies show that SAD most often precedes depression and that SAD is related to a substantially and consistently increase in risk of subsequent depression. Similarly, symptoms of social anxiety often precedes alcohol dependence. SAD is an adolescent-onset disorder with a long recovery period. Despite the prolonged recovery, few individuals with SAD seek treatment for their disorder. Only about one-third of lifetime cases report ever seeking treatment for SAD. Not seeking treatment may be related to the nature of the disorder itself. Individuals with SAD avoid treatment because the treatment itself constitutes a social situation that provokes anxiety. The treatment of choice for social anxiety is cognitive behavioral therapy (CBT). Treatment is conducted both individually and in group-settings. Exposure therapy is central to CBT and is very effective in fear reduction. In vivo exposure is effective when treating SAD, but conducting in vivo exposure in session can be challenging because relevant social situations might be difficult to obtain and control. In addition, finding the right setting for exposure can be time consuming and costly. Exposure in virtual reality has several advantages compared to in vivo exposure. Virtual reality provides readily available environments for exposure, such as a meeting room with a group of people waiting for the patient to give a presentation. Furthermore, exposure in VR is highly controllable and can be modified to fit the needs of the patient. Finally, exposure takes place in confidentiality within the safety of the therapy room and thus the threshold for initiating exposure might be lower than for in vivo exposure. AIMS AND HYPOTHESES Primary hypothesis: At post treatment the investigators expect that CBT including exposure therapy using individually tailored VR-content and a system to track anxiety levels (CBT-ExpVR) will result in lower levels of social anxiety than CBT with exposure in vivo (CBT-Exp). The outcome on social anxiety will be measured using the total score on Social Interaction Anxiety Scale (SIAS). Secondary hypotheses: At 6 and 12 months follow-up, the investigators expect that VR-treatment will result in lower levels of social anxiety than in vivo-treatment. Post treatment and at 6 and 12 months follow up the investigators expect that VR-treatment will result in lower levels of depression and higher levels of self-rated health than in vivo-treatment. The dropout rate the investigators expect will be lower for the VR-treatment compared to the in vivo-treatment. In addition to the evaluation of effect, a health economic evaluation will be made from a societal perspective. METHODS Design: The trial is a randomized controlled, assessor-blinded, parallel-group superiority trail. The study is conducted at Centre for Telepsychiatry in the Mental Health Services in the Region of Southern Denmark Participants and recruitment: Participants are referred to the trial's website where they are provided with written information about the study and are invited to complete online questionnaires screening for social anxiety symptoms and symptoms of depression. The questionnaire consists of Social Interaction Anxiety Scale and Major Depression Inventory and questions on current treatment and use of medication. Cut-off score for inclusion is <22 on SIAS and cut-off score for exclusion on MDI is >29. The online questionnaire might be supplemented by a phone call to inquire further information on current treatment and medication. No information will be obtained from patient records. Eligible participants are invited to an assessment at Centre for Telepsychiatry. The assessment will be carried out using the short version of the Present State Examination. Participants who meet the inclusion criteria will be offered to participate in the study. Before the pre-treatment assessment, included patients will be asked to complete an informed consent form. Randomization: Participants are block randomized (1:1) using random block size. The block sizes will not be disclosed, to ensure concealment. Computer generated random numbers using the platform Sealed Envelope (www.sealedeenvelope.com) will be used to generate the allocation sequence. The allocation sequence is handled by a data manager from the Patient data Explorative Network (OPEN) and is unavailable to those who enroll and assign participants. Blinding: Psychologist responsible for the diagnostic interview are blind to treatment assignment. Participants are blinded to their treatment assignment until their first treatment session. Participants will only be blind to treatment assignment at the pre-test but not at later assessments. A clinician blind to treatment assignment will administer the assessment taking place at pre-test, mid-test, and post-test. Sample size: A recent study reported approximately 10-point drop in SIAS for standard treatment involving CBT and 20-point drop for CBT with virtual exposure with standard deviations around 15 points. A drop of 13 points on SIAS is considered reliable change. If 35 participants are recruited for each group, this will lead to a statistical power of 0.80 comparing the VR-treatment to in vivo-treatment at the 0.05 significance level. To consider a 20% dropout the investigators plan to invite 90 participants in total. Fidelity: The interventions are manualized to increase treatment fidelity. To ensure that the treatment is delivered consistently and reliably in accordance with the manual the therapist will after each treatment session answer a self-report questionnaire on specific treatment targets for each session. Data collection and management: Data collected from the participants using self-report measures and data reported by therapist are collected using REDCap (Research Electronic Data Capture). To ensure confidentiality assigned researchers and the data manager at OPEN will be the only people with access to data at REDCap. Informed consent forms will be scanned and stored in REDCap . Data is stored at OPEN's server located in the Regions of Southern Denmark. Subjective Units of Distress Scale, Heart Rate, Electrodermal activity, and estimated anxiety are collected using iMotions, and data is saved on a secure folder on SharePoint. Statistical analyses: The primary statistical analysis will be carried out as intention to treat (ITT). The investigators will use linear mixed models to analyze the data. Separate analysis will be performed for each outcome variable. The investigators will use a two-level model with observations nested within participants. The fixed effects will be time, intervention, and the interaction between time and intervention as well as the baseline score. In addition to the primary analysis, a per-protocol analysis will be carried out on those participants completing at least 50% of the exposure sessions. A sensitivity analysis will be carried out where missing data will be handled by multiple imputation (m=100). Imputations will be based on baseline characteristics and secondary outcome measures using chained equations. The moderating effect of the working alliance, depressive symptoms, alcohol and drug use on the treatment outcome will be explored as subgroup analysis with continuous moderators by including them as covariates interacting with treatment and time. Model validation in the linear mixed model will be performed by inspection of QQ-plots of residuals and BLUPs (best linear unbiased predictors) to assess normality, and plotting residuals against fitted values to check homoscedasticity. If assumptions are violated, analysis will be performed after log-transformation. If assumptions do not hold on log-scale, bootstrapping will be applied. Monitoring: Cybersickness similar to motion sickness may occur in the VR-setting. Cybersickness will be monitored using the Simulator Sickness Questionnaire. Adverse events will be registered by the therapists. Dissemination policy: Results will be disseminated regardless of the magnitude or direction of effect. Both positive, negative, and inconclusive results will be made public and both beneficial and harmful effects of adaptive virtual reality exposure therapy will be reported. Dissemination will happen in scientific journals, at scientific conferences, as well as via www.clinicaltrials.gov. Authorship will be determined according to the Vancouver Guidelines

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Social Anxiety, Social Phobia
Keywords
Social anxiety, Cognitive behavioral therapy, Virtual reality, Exposure, Psychophysiological Measurement, Heart Rate, Electrodermal Activity

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
90 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Cognitive behavioral therapy with exposure in virtual reality
Arm Type
Experimental
Arm Description
This arm of the study will receive cognitive behavioral therapy with exposure in virtual reality. The intervention is individual and manualized and delivered by a psychologist. The intervention consists of 10 weekly session with a duration of 60 minutes. Exposure is conducted from session 4 to 9. Homework is assigned and it includes exposure in vivo. The amount of exposure is controlled for.
Arm Title
Cognitive behavioral therapy with exposure in vivo
Arm Type
Active Comparator
Arm Description
This arm of the study will receive cognitive behavioral therapy with exposure in vivo. The intervention is individual and manualized and delivered by a psychologist. The intervention consists of 10 weekly session with a duration of 60 minutes. Exposure is conducted from session 4 to 9. Homework is assigned and it includes exposure in vivo. The amount of exposure is controlled for.
Intervention Type
Behavioral
Intervention Name(s)
Cognitive behavioral therapy with exposure in virtual reality
Other Intervention Name(s)
CBT-ExpVR
Intervention Description
The treatment rationale is based on a model of the maintenance of social phobia by Clark and Wells. The themes of therapy are: a) The general ideas of CBT, b) The maintaining processes of social phobia, c) negative automatic thoughts, d) shifting focus of attention form self-focus to external focus, e) safety behaviors, f) post-processing, g) self-processing, h) schemas and rules for living. Exposure in VR: We will use 360° 3D videos for exposure using an HTC Vive Pro headset. Six different videos will be used for exposure: 1) Taking a seat on a bench in a public park, 2) Being introduced as a new employee, 3) Performing a presentation at a meeting, 4) Entering and shopping in a grocery store, 5) Visiting a café and 6) Using public transportation. The therapist can choose the length of the exposure as well as the difficulty of the exposure. While the participant is in the VR-scenario HR and EDA are measured. These data are collected to continuously estimate the anxiety levels.
Intervention Type
Behavioral
Intervention Name(s)
Cognitive behavioral therapy with exposure in vivo
Other Intervention Name(s)
CBT-Exp
Intervention Description
The treatment rationale is based on a model of the maintenance of social phobia by Clark and Wells.The themes of therapy are: a) The general ideas of CBT, b) The maintaining processes of social phobia, c) negative automatic thoughts, d) shifting focus of attention form self-focus to external focus, e) safety behaviors, f) post-processing, g) self-processing, h) schemas and rules for living. Exposure in vivo: Exposure is taking place at Centre for Telepsychiatry and the surrounding areas. The therapist is planning the exposure with the participant and is accompanying the participant during the exposure.
Primary Outcome Measure Information:
Title
Social Anxiety Interaction Scale
Description
The instrument is a measure of social anxiety symptoms and consists of 20 items assessing cognitive, affective, and behavioral responses to social interaction. The scale ranges from 0 to 80. Higher scores indicate worse outcome. Participants have to indicate to what degree they feel each statement is characteristic to them using a 5-point Likert scale (0 = not at all, 1 = slightly, 2 = moderately, 3 = very, 4 = extremely). The instrument has high internal consistency, Cronbach's alpha = 0.93, and high test-retest reliability, r = 0.92 (45).
Time Frame
post-treatment (week 10)
Secondary Outcome Measure Information:
Title
Leibowitz Anxiety Scale - Self report version
Description
Leibowitz Anxiety Scale - Self report version is a measure of anxiety and avoidance in a range of social situations.
Time Frame
post-treatment (week 10)
Title
Fear of Negative Evaluation - Brief version
Description
Fear of Negative Evaluation - Brief version is a measure of distress experiences when getting negative evaluations by others.
Time Frame
post-treatment (week 10)
Title
Major Depression inventory
Description
Major Depression inventory is a measure of symptoms severity in depression.
Time Frame
post-treatment (week 10)
Title
EQ-5D-5L
Description
EQ-5D-5L is a measure of health status.
Time Frame
post-treatment (week 10)
Title
Alcohol Use Disorders Identification Test
Description
Alcohol Use Disorders Identification Test is a screening for unhealthy alcohol use.
Time Frame
pre-treatment (week 1)
Title
Drug use disorders identification test
Description
Drug use disorders identification test is a screening instrument for drug-related problems.
Time Frame
pre-treatment (week 1)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Sufficient knowledge of the Danish Language. Fulfilling the diagnostic criteria for SAD according to ICD-10 classification of mental and behavioral disorders (F 40.1). Exclusion Criteria: Previously diagnosed with autism spectrum disorders. Previously diagnosed with psychotic disorders. Severe depression (>29 Major Depression Inventory) Dependence syndrome Suicidal ideation. Dementia/Intellectual disability. Epilepsy. Taking part in other kinds of psychological intervention for SAD. Medication (SSRI, benzodiazepine, MAOI) type and doses needs to be stable three months prior to inclusions and during the intervention.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Per Trads Ørskov, Ph.d.
Phone
+4521317739
Email
per.trads.orskov@rsyd.dk
First Name & Middle Initial & Last Name or Official Title & Degree
Mia Beck Lictenstein, Ph.d.
Email
mialic@rsyd.dk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Per Trads Ørskov, Ph.d.
Organizational Affiliation
Region of Southern Denmark
Official's Role
Principal Investigator
Facility Information:
Facility Name
Centre for Telepsychiatry
City
Odense C
State/Province
Denmark/Region Of Southern Denmark
ZIP/Postal Code
5000
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Per T Ørskov, Ph.d.
Phone
+4521317739
Email
per.trads.orskov@rsyd.dk
First Name & Middle Initial & Last Name & Degree
Mia B Lichtenstein, Ph.d.
Email
mialic@rsyd.dk

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Data will be stored on a server located in the Region of Southern Denmark. February 2025 data will be transferred to The Danish National Archives. Data are available upon reasonable request. Restrictions apply to the availability of data and approval is needed from Danish Data Protection Agency and or The Danish National Archives.
IPD Sharing Time Frame
February 2025
IPD Sharing Access Criteria
Restrictions apply to the availability of data and approval is needed from Danish Data Protection Agency and or The Danish National Archives.
Citations:
Citation
Organization, W. H. (1992). The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines, World Health Organization.
Results Reference
background
PubMed Identifier
17976249
Citation
Ruscio AM, Brown TA, Chiu WT, Sareen J, Stein MB, Kessler RC. Social fears and social phobia in the USA: results from the National Comorbidity Survey Replication. Psychol Med. 2008 Jan;38(1):15-28. doi: 10.1017/S0033291707001699. Epub 2007 Nov 2.
Results Reference
background
PubMed Identifier
25122449
Citation
Crome E, Grove R, Baillie AJ, Sunderland M, Teesson M, Slade T. DSM-IV and DSM-5 social anxiety disorder in the Australian community. Aust N Z J Psychiatry. 2015 Mar;49(3):227-35. doi: 10.1177/0004867414546699. Epub 2014 Aug 13.
Results Reference
background
PubMed Identifier
16299426
Citation
Stein MB, Roy-Byrne PP, Craske MG, Bystritsky A, Sullivan G, Pyne JM, Katon W, Sherbourne CD. Functional impact and health utility of anxiety disorders in primary care outpatients. Med Care. 2005 Dec;43(12):1164-70. doi: 10.1097/01.mlr.0000185750.18119.fd.
Results Reference
background
PubMed Identifier
17679635
Citation
Beesdo K, Bittner A, Pine DS, Stein MB, Hofler M, Lieb R, Wittchen HU. Incidence of social anxiety disorder and the consistent risk for secondary depression in the first three decades of life. Arch Gen Psychiatry. 2007 Aug;64(8):903-12. doi: 10.1001/archpsyc.64.8.903.
Results Reference
background
PubMed Identifier
10713800
Citation
Heimberg RG, Stein MB, Hiripi E, Kessler RC. Trends in the prevalence of social phobia in the United States: a synthetic cohort analysis of changes over four decades. Eur Psychiatry. 2000 Feb;15(1):29-37. doi: 10.1016/s0924-9338(00)00213-3.
Results Reference
background
PubMed Identifier
27979818
Citation
Bouchard S, Dumoulin S, Robillard G, Guitard T, Klinger E, Forget H, Loranger C, Roucaut FX. Virtual reality compared with in vivo exposure in the treatment of social anxiety disorder: a three-arm randomised controlled trial. Br J Psychiatry. 2017 Apr;210(4):276-283. doi: 10.1192/bjp.bp.116.184234. Epub 2016 Dec 15.
Results Reference
background
PubMed Identifier
21479777
Citation
Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011 Dec;20(10):1727-36. doi: 10.1007/s11136-011-9903-x. Epub 2011 Apr 9.
Results Reference
background
PubMed Identifier
12622314
Citation
Olsen LR, Jensen DV, Noerholm V, Martiny K, Bech P. The internal and external validity of the Major Depression Inventory in measuring severity of depressive states. Psychol Med. 2003 Feb;33(2):351-6. doi: 10.1017/s0033291702006724.
Results Reference
background
PubMed Identifier
9670605
Citation
Mattick RP, Clarke JC. Development and validation of measures of social phobia scrutiny fear and social interaction anxiety. Behav Res Ther. 1998 Apr;36(4):455-70. doi: 10.1016/s0005-7967(97)10031-6.
Results Reference
background
PubMed Identifier
19589161
Citation
Tavoli A, Melyani M, Bakhtiari M, Ghaedi GH, Montazeri A. The Brief Fear of Negative Evaluation Scale (BFNE): translation and validation study of the Iranian version. BMC Psychiatry. 2009 Jul 9;9:42. doi: 10.1186/1471-244X-9-42.
Results Reference
background
PubMed Identifier
8329970
Citation
Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II. Addiction. 1993 Jun;88(6):791-804. doi: 10.1111/j.1360-0443.1993.tb02093.x.
Results Reference
background
PubMed Identifier
25682718
Citation
Hildebrand M. The Psychometric Properties of the Drug Use Disorders Identification Test (DUDIT): A Review of Recent Research. J Subst Abuse Treat. 2015 Jun;53:52-9. doi: 10.1016/j.jsat.2015.01.008. Epub 2015 Jan 31.
Results Reference
background
Citation
Kennedy, R. S., Lane, N. E., Berbaum, K. S., & Lilienthal, M. G. (1993). Simulator Sickness Questionnaire: An enhanced method for quantifying simulator sickness. The International Journal of Aviation Psychology, 3(3), 203-220. https://doi.org/10.1207/s15327108ijap0303_3
Results Reference
background
Citation
Horvath, A. O., & Greenberg, L. S. (1989). Development and validation of the Working Alliance Inventory. Journal of Counseling Psychology, 36(2), 223-233. https://doi.org/10.1037/0022-0167.36.2.223
Results Reference
background
PubMed Identifier
21685650
Citation
Robillard G, Bouchard S, Dumoulin S, Guitard T. The development of the SWEAT questionnaire: a scale measuring costs and efforts inherent to conducting exposure sessions. Stud Health Technol Inform. 2011;167:105-10.
Results Reference
background
PubMed Identifier
36299540
Citation
Orskov PT, Lichtenstein MB, Ernst MT, Fasterholdt I, Matthiesen AF, Scirea M, Bouchard S, Andersen TE. Cognitive behavioral therapy with adaptive virtual reality exposure vs. cognitive behavioral therapy with in vivo exposure in the treatment of social anxiety disorder: A study protocol for a randomized controlled trial. Front Psychiatry. 2022 Oct 10;13:991755. doi: 10.3389/fpsyt.2022.991755. eCollection 2022.
Results Reference
derived

Learn more about this trial

Virtual Reality for AnxIety Disorders - Randomized Controlled Trial

We'll reach out to this number within 24 hrs